Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease

Katharine Whartenby, Peter Calabresi, Erin McCadden, Bao Nguyen, David Kardian, Tianhong Wang, Claudio Mosse, Andrew Mark Pardoll, Donald Small

Research output: Contribution to journalArticle

Abstract

Autoimmune diseases often result from inappropriate or unregulated activation of autoreactive T cells. Traditional approaches to treatment of autoimmune diseases through immunosuppression have focused on direct inhibition of T cells. In the present study, we examined the targeted inhibition of antigen-presenting cells as a means to downregulate immune responses and treat autoimmune disease. Dendritic cells (DCs) are the central antigen-presenting cells for the initiation of T cell responses, including autoreactive ones. A large portion of DCs are derived from hematopoietic progenitors that express FLT3 receptor (CD135), and stimulation of the receptor via FLT3 ligand either in vivo or in vitro is known to drive expansion and differentiation of these progenitors toward a DC phenotype. We hypothesized that inhibition of FLT3 signaling would thus produce an inhibition of DC-induced stimulation of T cells, thereby inhibiting autoimmune responses. To this end, we used small-molecule tyrosine kinase inhibitors targeted against FLT3 and examined the effects on DCs and their role in the promulgation of autoimmune disease. Results of our studies show that inhibition of FLT3 signaling induces apoptosis in both mouse and human DCs, and thus is a potential target for immune suppression. Furthermore, targeted inhibition of FLT3 significantly improved the course of established disease in a model for multiple sclerosis, experimental autoimmune encephalomyelitis, suggesting a potential avenue for treating autoimmune disease.

Original languageEnglish (US)
Pages (from-to)16741-16746
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume102
Issue number46
DOIs
StatePublished - Nov 15 2005

Fingerprint

Dendritic Cells
Autoimmune Diseases
T-Lymphocytes
Antigen-Presenting Cells
Autoimmune Experimental Encephalomyelitis
Autoimmunity
Protein-Tyrosine Kinases
Immunosuppression
Multiple Sclerosis
Down-Regulation
Apoptosis
Ligands
Phenotype

Keywords

  • Autoimmune disease
  • FLT3 ligand

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. / Whartenby, Katharine; Calabresi, Peter; McCadden, Erin; Nguyen, Bao; Kardian, David; Wang, Tianhong; Mosse, Claudio; Pardoll, Andrew Mark; Small, Donald.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 46, 15.11.2005, p. 16741-16746.

Research output: Contribution to journalArticle

@article{d580150db191477396bce1f1dab21e12,
title = "Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease",
abstract = "Autoimmune diseases often result from inappropriate or unregulated activation of autoreactive T cells. Traditional approaches to treatment of autoimmune diseases through immunosuppression have focused on direct inhibition of T cells. In the present study, we examined the targeted inhibition of antigen-presenting cells as a means to downregulate immune responses and treat autoimmune disease. Dendritic cells (DCs) are the central antigen-presenting cells for the initiation of T cell responses, including autoreactive ones. A large portion of DCs are derived from hematopoietic progenitors that express FLT3 receptor (CD135), and stimulation of the receptor via FLT3 ligand either in vivo or in vitro is known to drive expansion and differentiation of these progenitors toward a DC phenotype. We hypothesized that inhibition of FLT3 signaling would thus produce an inhibition of DC-induced stimulation of T cells, thereby inhibiting autoimmune responses. To this end, we used small-molecule tyrosine kinase inhibitors targeted against FLT3 and examined the effects on DCs and their role in the promulgation of autoimmune disease. Results of our studies show that inhibition of FLT3 signaling induces apoptosis in both mouse and human DCs, and thus is a potential target for immune suppression. Furthermore, targeted inhibition of FLT3 significantly improved the course of established disease in a model for multiple sclerosis, experimental autoimmune encephalomyelitis, suggesting a potential avenue for treating autoimmune disease.",
keywords = "Autoimmune disease, FLT3 ligand",
author = "Katharine Whartenby and Peter Calabresi and Erin McCadden and Bao Nguyen and David Kardian and Tianhong Wang and Claudio Mosse and Pardoll, {Andrew Mark} and Donald Small",
year = "2005",
month = "11",
day = "15",
doi = "10.1073/pnas.0506088102",
language = "English (US)",
volume = "102",
pages = "16741--16746",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "46",

}

TY - JOUR

T1 - Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease

AU - Whartenby, Katharine

AU - Calabresi, Peter

AU - McCadden, Erin

AU - Nguyen, Bao

AU - Kardian, David

AU - Wang, Tianhong

AU - Mosse, Claudio

AU - Pardoll, Andrew Mark

AU - Small, Donald

PY - 2005/11/15

Y1 - 2005/11/15

N2 - Autoimmune diseases often result from inappropriate or unregulated activation of autoreactive T cells. Traditional approaches to treatment of autoimmune diseases through immunosuppression have focused on direct inhibition of T cells. In the present study, we examined the targeted inhibition of antigen-presenting cells as a means to downregulate immune responses and treat autoimmune disease. Dendritic cells (DCs) are the central antigen-presenting cells for the initiation of T cell responses, including autoreactive ones. A large portion of DCs are derived from hematopoietic progenitors that express FLT3 receptor (CD135), and stimulation of the receptor via FLT3 ligand either in vivo or in vitro is known to drive expansion and differentiation of these progenitors toward a DC phenotype. We hypothesized that inhibition of FLT3 signaling would thus produce an inhibition of DC-induced stimulation of T cells, thereby inhibiting autoimmune responses. To this end, we used small-molecule tyrosine kinase inhibitors targeted against FLT3 and examined the effects on DCs and their role in the promulgation of autoimmune disease. Results of our studies show that inhibition of FLT3 signaling induces apoptosis in both mouse and human DCs, and thus is a potential target for immune suppression. Furthermore, targeted inhibition of FLT3 significantly improved the course of established disease in a model for multiple sclerosis, experimental autoimmune encephalomyelitis, suggesting a potential avenue for treating autoimmune disease.

AB - Autoimmune diseases often result from inappropriate or unregulated activation of autoreactive T cells. Traditional approaches to treatment of autoimmune diseases through immunosuppression have focused on direct inhibition of T cells. In the present study, we examined the targeted inhibition of antigen-presenting cells as a means to downregulate immune responses and treat autoimmune disease. Dendritic cells (DCs) are the central antigen-presenting cells for the initiation of T cell responses, including autoreactive ones. A large portion of DCs are derived from hematopoietic progenitors that express FLT3 receptor (CD135), and stimulation of the receptor via FLT3 ligand either in vivo or in vitro is known to drive expansion and differentiation of these progenitors toward a DC phenotype. We hypothesized that inhibition of FLT3 signaling would thus produce an inhibition of DC-induced stimulation of T cells, thereby inhibiting autoimmune responses. To this end, we used small-molecule tyrosine kinase inhibitors targeted against FLT3 and examined the effects on DCs and their role in the promulgation of autoimmune disease. Results of our studies show that inhibition of FLT3 signaling induces apoptosis in both mouse and human DCs, and thus is a potential target for immune suppression. Furthermore, targeted inhibition of FLT3 significantly improved the course of established disease in a model for multiple sclerosis, experimental autoimmune encephalomyelitis, suggesting a potential avenue for treating autoimmune disease.

KW - Autoimmune disease

KW - FLT3 ligand

UR - http://www.scopus.com/inward/record.url?scp=28044445893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044445893&partnerID=8YFLogxK

U2 - 10.1073/pnas.0506088102

DO - 10.1073/pnas.0506088102

M3 - Article

VL - 102

SP - 16741

EP - 16746

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 46

ER -